These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

627 related items for PubMed ID: 23639294

  • 1. Early serum hepatitis B virus large surface protein level: a stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B.
    Zhu X, Gong Q, Yu D, Zhang D, Gu L, Han Y, Chen J, Zhang Y, Zhang X.
    J Clin Virol; 2013 Aug; 57(4):318-22. PubMed ID: 23639294
    [Abstract] [Full Text] [Related]

  • 2. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.
    Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, Simon K, Akarca US, Flisiak R, Verhey E, Van Vuuren AJ, Boucher CA, ter Borg MJ, Janssen HL.
    Hepatology; 2010 Aug; 52(2):454-61. PubMed ID: 20683945
    [Abstract] [Full Text] [Related]

  • 3. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
    Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, Tang H, Sheng J, Zhao M.
    J Hepatol; 2014 Oct; 61(4):777-84. PubMed ID: 24915612
    [Abstract] [Full Text] [Related]

  • 4. Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.
    Peng CY, Lai HC, Li YF, Su WP, Chuang PH, Kao JT.
    Aliment Pharmacol Ther; 2012 Feb; 35(4):458-68. PubMed ID: 22225574
    [Abstract] [Full Text] [Related]

  • 5. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype.
    Brunetto MR, Marcellin P, Cherubini B, Yurdaydin C, Farci P, Hadziyannis SJ, Rothe V, Regep L, Bonino F.
    J Hepatol; 2013 Dec; 59(6):1153-9. PubMed ID: 23872601
    [Abstract] [Full Text] [Related]

  • 6. Quantitative hepatitis B surface antigen combined with hepatitis B e antigen as sustained virological response predictors during extended therapy with Peginterferon alfa-2a for hepatitis B e antigen-positive chronic hepatitis B.
    Chen J, Zhang DH, Xu CR, Zhu MY, Yang ZT, Gong QM, Yu DM, Zhang XX.
    J Clin Virol; 2015 Nov; 72():88-94. PubMed ID: 26476325
    [Abstract] [Full Text] [Related]

  • 7. On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients.
    Goulis I, Karatapanis S, Akriviadis E, Deutsch M, Dalekos GN, Raptopoulou-Gigi M, Mimidis K, Germanidis G, Drakoulis C, Triantos C, Zintzaras E, Bakalos G, Papatheodoridis G.
    Liver Int; 2015 May; 35(5):1540-8. PubMed ID: 25368957
    [Abstract] [Full Text] [Related]

  • 8. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.
    Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Luo K, Wang Y, Hadziyannis S, Wolf E, McCloud P, Batrla R, Marcellin P.
    Hepatology; 2009 Apr; 49(4):1141-50. PubMed ID: 19338056
    [Abstract] [Full Text] [Related]

  • 9. Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients.
    Chan HL, Wong GL, Chim AM, Chan HY, Chu SH, Wong VW.
    Antivir Ther; 2011 Apr; 16(8):1249-57. PubMed ID: 22155906
    [Abstract] [Full Text] [Related]

  • 10. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
    He LT, Ye XG, Zhou XY.
    World J Gastroenterol; 2016 Dec 14; 22(46):10210-10218. PubMed ID: 28028369
    [Abstract] [Full Text] [Related]

  • 11. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.
    Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, Dauvergne A, Asselah T, Boyer N, Bedossa P, Valla D, Vidaud M, Nicolas-Chanoine MH, Marcellin P.
    Hepatology; 2009 Apr 14; 49(4):1151-7. PubMed ID: 19115222
    [Abstract] [Full Text] [Related]

  • 12. CD56bright natural killer cells induce HBsAg reduction via cytolysis and cccDNA decay in long-term entecavir-treated patients switching to peginterferon alfa-2a.
    Shi A, Zhang X, Xiao F, Zhu L, Yan W, Han M, Luo X, Chen T, Ning Q.
    J Viral Hepat; 2018 Nov 14; 25(11):1352-1362. PubMed ID: 29888839
    [Abstract] [Full Text] [Related]

  • 13. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
    Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N, Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group.
    N Engl J Med; 2005 Jun 30; 352(26):2682-95. PubMed ID: 15987917
    [Abstract] [Full Text] [Related]

  • 14. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B.
    Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G, Luo KX, Paik SW, Liaw YF, Button P, Popescu M.
    Hepatology; 2008 Feb 30; 47(2):428-34. PubMed ID: 18220290
    [Abstract] [Full Text] [Related]

  • 15. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.
    Li GJ, Yu YQ, Chen SL, Fan P, Shao LY, Chen JZ, Li CS, Yi B, Chen WC, Xie SY, Mao XN, Zou HH, Zhang WH.
    Antimicrob Agents Chemother; 2015 Jul 30; 59(7):4121-8. PubMed ID: 25941216
    [Abstract] [Full Text] [Related]

  • 16. [HBeAg seroconversion achieved by sequential peginterferon alfa-2a therapy in chronic hepatitis B patients with unsatisfactory end point following entecavir treatment].
    Chen XF, Chen XP, Ma XJ, Chen WL, Luo XD, Liao JY.
    Zhonghua Gan Zang Bing Za Zhi; 2013 Jul 30; 21(7):502-5. PubMed ID: 24074707
    [Abstract] [Full Text] [Related]

  • 17. Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: a Romanian cohort study.
    Gheorghiţa VI, Caruntu FA, Curescu M, Olaru I, Radu MN, Colţan G, Streinu-Cercel A.
    J Gastrointestin Liver Dis; 2013 Mar 30; 22(1):27-32. PubMed ID: 23539387
    [Abstract] [Full Text] [Related]

  • 18. Quantitation of large, middle and small hepatitis B surface proteins in HBeAg-positive patients treated with peginterferon alfa-2a.
    Rinker F, Bremer CM, Schröder K, Wiegand SB, Bremer B, Manns MP, Kraft AR, Wedemeyer H, Yang L, Pavlovic V, Wat C, Gerlich WH, Glebe D, Cornberg M.
    Liver Int; 2020 Feb 30; 40(2):324-332. PubMed ID: 31721419
    [Abstract] [Full Text] [Related]

  • 19. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
    Cao ZH, Ma LN, Zhang HW, Liu YL, Chen XY.
    J Dig Dis; 2013 Aug 30; 14(8):446-50. PubMed ID: 23615131
    [Abstract] [Full Text] [Related]

  • 20. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels.
    Sonneveld MJ, Hansen BE, Piratvisuth T, Jia JD, Zeuzem S, Gane E, Liaw YF, Xie Q, Heathcote EJ, Chan HL, Janssen HL.
    Hepatology; 2013 Sep 30; 58(3):872-80. PubMed ID: 23553752
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.